CD274 and non-small cell lung carcinoma: With further study of the mechanism of tumorigenesis and the development of molecular detection, programmed cell death protein-1 (PD-1) /programmed death-ligand-1 (PD-L1) monoclonal antibodies have become the first-line therapy for advanced NSCLC patients 2.